(Total Views: 292)
Posted On: 04/09/2018 11:58:12 AM
Post# of 72442
Pete, you do not understand how clinical trials work. If there had been deaths in a Phase 1 trial, the trial would have been ended immediately. They would have been gambling the company's entire future.
It would be criminally irresponsible to start with a high dose of a completely new type of drug -- especially since the OTHER drugs that tried to modulate p53 had very serious side effects.
Do you want an example? PolyMedix started with what we now know were very high doses of Brilacidin. The side effects from these massive doses were enough to make them think that the drug trial was not worth pursuing.
It was the genius of Dr. Menon in recognizing that they had started with a much larger dose than they should have that has made it possible for IPIX to have these incredibly successful, minimal-side-effect clinical trials.
How about this example: the French drug company that killed several patients by starting them on high doses. Or any number of other clinical trials that have killed people because they weren't cautious.
I'm glad that we have a management that puts safety first.
It would be criminally irresponsible to start with a high dose of a completely new type of drug -- especially since the OTHER drugs that tried to modulate p53 had very serious side effects.
Do you want an example? PolyMedix started with what we now know were very high doses of Brilacidin. The side effects from these massive doses were enough to make them think that the drug trial was not worth pursuing.
It was the genius of Dr. Menon in recognizing that they had started with a much larger dose than they should have that has made it possible for IPIX to have these incredibly successful, minimal-side-effect clinical trials.
How about this example: the French drug company that killed several patients by starting them on high doses. Or any number of other clinical trials that have killed people because they weren't cautious.
I'm glad that we have a management that puts safety first.
(1)
(0)Scroll down for more posts ▼
